Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC
02. November 2023 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Participate in Three Upcoming Investor Conferences
30. Oktober 2023 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Oct. 30, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Reports First Quarter 2023 Financial Results
10. Mai 2023 16:03 ET
|
Kura Oncology, Inc.
– Evolving data from Phase 1 trial of ziftomenib in NPM1-mutant AML to be presented at EHA – – Site activation and enrollment in Phase 2 registration-directed trial of ziftomenib in NPM1-mutant AML...
Kura Oncology to Report First Quarter 2023 Financial Results
03. Mai 2023 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, May 03, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology Reports Preclinical Data Highlighting Synergistic Activity of Farnesyl Transferase Inhibitor in Combination with Targeted Therapies
17. April 2023 07:30 ET
|
Kura Oncology, Inc.
– Preclinical data support the potential for FTIs in combination with KRASG12C inhibitors and TKIs to prevent or delay emergence of adaptive resistance – – Company preparing to initiate Phase 1...
Kura Oncology Announces Acceptance of Two Abstracts for Presentation at AACR Annual Meeting
14. März 2023 17:32 ET
|
Kura Oncology, Inc.
– Presentations to highlight preclinical data supporting combination of FTIs with KRASG12C inhibitors and tyrosine kinase inhibitors – SAN DIEGO, March 14, 2023 (GLOBE NEWSWIRE) -- Kura Oncology,...
Kura Oncology to Participate in Upcoming Investor Conferences
01. März 2023 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, March 01, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Reports Fourth Quarter and Full Year 2022 Financial Results
23. Februar 2023 16:03 ET
|
Kura Oncology, Inc.
– Phase 1 data for ziftomenib highlighted by 30% CR rate among 20 patients with NPM1-mutant AML treated at recommended Phase 2 dose – – Multiple patients dosed in registration-directed trial of...
Kura Oncology to Report Fourth Quarter and Full Year 2022 Financial Results
16. Februar 2023 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 16, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology to Participate in SVB Securities Global Biopharma Conference
07. Februar 2023 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...